Scapa Group PLC Acquisition (5953C)

TIDMSCPA

RNS Number : 5953C

Scapa Group PLC

02 October 2018

2 October 2018

LEI No. 213800QIPVTK5ES5UU36

Scapa Group plc ("Scapa" or "the Group")

Completion of Acquisition of Systagenix Advanced Wound Dressing Facility in Gargrave

Entering a 5-year exclusive manufacturing and supply agreement

Further to the announcement made on 13 September 2018, Scapa Group plc (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018. In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.

For further information:

 
 Scapa Group plc 
  Heejae Chae - Group Chief Executive 
  Oskar Zahn - Chief Financial Officer      0161 301 7430 
 Numis Securities Limited 
  (Nominated Adviser and Joint Broker) 
  Richard Thomas/Mark Lander               020 7260 1000 
 
 
   Berenberg 
   (Joint Broker)                           020 3207 7800 
   Chris Bowman 
 
   Weber Shandwick Financial PR 
   Nick Oborne                              020 7067 0000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACQBUBDGRSGBGIB

(END) Dow Jones Newswires

October 02, 2018 02:00 ET (06:00 GMT)

Scapa (LSE:SCPA)
Historical Stock Chart
From Apr 2024 to May 2024